{"id":9538,"date":"2020-06-11T17:59:57","date_gmt":"2020-06-11T12:29:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9538"},"modified":"2023-02-10T11:43:21","modified_gmt":"2023-02-10T06:13:21","slug":"recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent","title":{"rendered":"AbbVie &#038; Genmab\u2019s Collaboration; Lilly&#8217;s antisense neuro deal; COVID-19 treatment updates; Roche\u2019s partnership with Innovent;"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e49802e8da9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e49802e8da9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent\/#AbbVie_Seals_a_USD_750_M_Bispecific_Antibody_Cancer_Drug_Deal_with_Genmab\" >AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent\/#Eli_Lilly_inks_antisense_neuro_deal_with_Evox_Therapeutics\" >Eli&nbsp;Lilly inks antisense neuro deal with Evox Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent\/#Deciphering_new_treatments_for_COVID-19\" >Deciphering new treatments for COVID-19<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent\/#Roche_inks_USD_2_Billion_deal_with_Innovent_Biologics\" >Roche inks USD 2 Billion deal with Innovent Biologics&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-seals-a-usd-750-m-bispecific-antibody-cancer-drug-deal-with-genmab\"><span class=\"ez-toc-section\" id=\"AbbVie_Seals_a_USD_750_M_Bispecific_Antibody_Cancer_Drug_Deal_with_Genmab\"><\/span><strong>AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Regeneron to market with a bispecific antibody that could contest with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T therapies<\/a><\/strong>.&nbsp;<\/p>\n\n\n\n<p>Genmab has always targeted a mid-2020 deal, including the rights to CD3xCD20 bispecific antibody epcoritamab.<\/p>\n\n\n\n<p>Now, AbbVie has landed rights to epcoritamab by approving to Genmab\u2019s redlines for the agreement, putting up USD 750 million upfront and committing to a collaboration that extends far beyond epcoritamab.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-inks-antisense-neuro-deal-with-evox-therapeutics\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_inks_antisense_neuro_deal_with_Evox_Therapeutics\"><\/span><strong>Eli<\/strong>&nbsp;<strong>Lilly inks antisense neuro deal with Evox Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Eli Lilly is penning a new pipeline agreement in central nervous system diseases. It is in partnership with U.K.-based exosome therapeutics firm- Evox Therapeutics will receive the delivery of RNA interference and antisense oligonucleotide drug for neurological disorders.<\/p>\n\n\n\n<p>The upfront is USD 20 million, with Lilly also funnelling a USD10 million investment in exchange for a convertible bond from Evox.<\/p>\n\n\n\n<p>Under the deal that is centred around a five-target license agreement, Evox will be responsible for exosome engineering in order to get brain\/CNS-targeting, drug loading and analytics and some in vitro assay development, and material supply for initial in vivo studies as well. Moreover, Eli Lilly will only step in to acquire once this has been finished. Specific details on targets were not released.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deciphering-new-treatments-for-covid-19\"><span class=\"ez-toc-section\" id=\"Deciphering_new_treatments_for_COVID-19\"><\/span><strong>Deciphering new treatments for COVID-19<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As the highly infectious novel coronavirus is continuously spreading, scientists are questing for new ways to kill the virus. While the antiviral remdesivir of Gilead Sciences has shown activity against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19<\/strong><\/a>, though its clinical benefits may be limited, thus resulting in a demand for better treatments.<\/p>\n\n\n\n<p>Now, Ernesto Estrada at the University of Zaragoza in Spain has found what could be the weakness of <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\"><strong>SARS-<\/strong><\/a><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">C<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\"><strong>oV-2<\/strong><\/a>, the virus that causes <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>COVID-19<\/strong><\/a>. It is a protein, which is required for the reproduction of the virus, making it a perfect target for potential drugs as per him.<\/p>\n\n\n\n<p>The protein is known as main protease (Mpro). It is an enzyme, which cuts precursor molecules that are translated from viral RNA to make functional viral proteins. Proteases are drug targets due to their imperative role in viral replication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-inks-usd-2-billion-deal-with-innovent-biologics\"><span class=\"ez-toc-section\" id=\"Roche_inks_USD_2_Billion_deal_with_Innovent_Biologics\"><\/span><strong>Roche inks USD 2 Billion deal with Innovent Biologics&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche is licensing out part of its cancer platform to Chinese biotech Innovent Biologics. Innovent gets non-exclusive access to the Swiss major\u2019s cell therapies and bispecific antibodies for both blood and solid cancers.<\/p>\n\n\n\n<p>Under the deal, Innovent has to create, develop, manufacture, and commercialize the products, while Roche keeps an option to license each product for development and sale outside of China.<\/p>\n\n\n\n<p>Hoffmann-La Roche joins Incyte, Eli Lilly, and the MD Anderson Cancer Center in collaboration with the high-rising biotech that came into focus in 2018 when it raised USD 421 million in a Hong Kong IPO.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab&nbsp;&nbsp; AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Regeneron to market with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9546,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,10830,228,18445,17453,1315,524],"industry":[17225],"therapeutic_areas":[17231,17243],"class_list":["post-9538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-covid-19","tag-eli-lilly","tag-evox-therapeutics","tag-genmab","tag-innovent-biologics","tag-roche","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News Updates | AbbVie, Eli Lilly, Roche, Gilead Sciences<\/title>\n<meta name=\"description\" content=\"AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News Updates | AbbVie, Eli Lilly, Roche, Gilead Sciences\" \/>\n<meta property=\"og:description\" content=\"AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-11T12:29:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:13:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/11153540\/Nesw.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News Updates | AbbVie, Eli Lilly, Roche, Gilead Sciences","description":"AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent","og_locale":"en_US","og_type":"article","og_title":"Pharma News Updates | AbbVie, Eli Lilly, Roche, Gilead Sciences","og_description":"AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-11T12:29:57+00:00","article_modified_time":"2023-02-10T06:13:21+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/11153540\/Nesw.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent","name":"Pharma News Updates | AbbVie, Eli Lilly, Roche, Gilead Sciences","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/11153540\/Nesw.png","datePublished":"2020-06-11T12:29:57+00:00","dateModified":"2023-02-10T06:13:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-eli-lilly-evox-roche-innovent#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/11153540\/Nesw.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/11153540\/Nesw.png","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/11153540\/Nesw-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Evox Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genmab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Innovent Biologics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Evox Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Genmab<\/span>","<span class=\"advgb-post-tax-term\">Innovent Biologics<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 11, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Jun 11, 2020 5:59 pm","modified":"Updated on Feb 10, 2023 11:43 am"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9538"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9546"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9538"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9538"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}